Patents by Inventor Claudius Weiler

Claudius Weiler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050042178
    Abstract: The invention relates to inhalable powders in the form of stable, spray-dried microparticles (embedding particles) for pulmonary or nasal inhalation, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or a physiologically acceptable salt thereof and one or more excipients, processes for preparing such microparticles and the use thereof for preparing a powder inhalant for the treatment of headaches, migraine and cluster headache.
    Type: Application
    Filed: July 29, 2004
    Publication date: February 24, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Michael Trunk, Claudius Weiler
  • Publication number: 20050043247
    Abstract: The invention relates to the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof which are stable in the amorphous state under normal conditions (T<50° C., relative humidity<75%) and are in the form of microparticles, processes for preparing such microparticles from these substances and the use of these particles for preparing a pharmaceutical composition of the inhalable powder type for pulmonary and nasal inhalation, particularly for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache.
    Type: Application
    Filed: July 29, 2004
    Publication date: February 24, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Michael Trunk, Claudius Weiler
  • Publication number: 20040014679
    Abstract: The invention relates to an inhalation powder for treating migraine, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I as the active substance base in the form of spherically nanostructured microparticles, and a process for the manufacture thereof.
    Type: Application
    Filed: February 12, 2003
    Publication date: January 22, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventors: Michael Trunk, Claudius Weiler
  • Publication number: 20030191068
    Abstract: The invention relates to salts of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine[BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.
    Type: Application
    Filed: February 12, 2003
    Publication date: October 9, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Michael Trunk, Claudius Weiler